In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme

Inclusion Criteria: * Healthy subjects (n=40): 18-50 years old male and female subjects without any conditions or taking any agents or food supplements that may influence platelet function as determined by the study principal investigator. * Subjects with CV risk factors (n=40): 18-50 years old male and female subjects with at least three of the following CV risk factors: History of hypercholesterolemia, hypertension, overweight, current smoker, prediabetes or diabetes who are only on metformin and insulin, and family history of coronary artery, peripheral artery, or cerebrovascular disease. Overweight is defined as subjects with BMI ≥25 kg/m2 (https://www.heart.org/en/healthy-living/healthy-eating/losing-weight/bmi-in-adults). Diabetes is defined as haemoglobin (Hb)A1c ≥6.5%, prediabetes =5.7%-6.4%) (https://diabetes.org/about-diabetes/diagnosis) Exclusion Criteria: * Subjects with Diabetes mellitus, who are on GLP-1 agonists or SGLT2 inhibitors. * Subjects on high dose statin therapy or PCSK9 therapy. * Prior coronary of cerebrovascular event requiring intervention. * Use of any antiplatelet or anticoagulant therapy within 14 days of enrollment. * Subjects with a history of chronic kidney disease, liver disease, pancreatitis, HIV, hepatitis, and active cancer, active infection, or any other medical condition or concomitant medications as determined by the investigator that may affect study results. * Pregnant